Scholars Central

Conference abstractPublished 15 Apr 2019

Estimation of causal equivalence effects in clinical bioequivalence/biosimilar studies in the presence of intercurrent events: Noncompliance and missing data

Authors: Wanjie Sun

FDA, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In equivalence, biosimilar, and non-inferiority studies, intent-to-treat (ITT) analysis tends to make the two treatments look similar, thereby is generally anti-conservative. The Per Protocol (PP) analysis based on completers and compliers is more able to reflect treatment differences and is usually preferred in equivalence assessment. In clinical endpoint bioequivalence studies, the current primary analysis for assessing equivalence between a generic and an innovator product is usually based on the observed per-protocol (PP) population. However, missing data and non-compliance are post-randomization intercurrent events and may introduce selection bias. Therefore, PP analysis is generally not causal. The FDA Missing Data Working Group (2016) recommended using “causal estimands of primary interest.” In this paper, we propose a principal stratification causal framework and co-primary causal estimands to test equivalence, which was one of the approaches recommended by the recently published ICH E9 (R1) addendum to address intercurrent events. We identify three conditions under which the current PP estimator is unbiased for one of the proposed co-primary causal estimands-the “Survivor Average Causal Effect” (SACE) estimand. Simulation shows that when these three conditions are not met, the PP estimator is biased, and may inflate Type 1 error and/or change power. We also propose a tipping point sensitivity analysis to evaluate the robustness of the current PP estimator in testing equivalence when the sensitivity parameters deviate from the three identified conditions, but stay within a clinically meaningful range. Our work is the first causal equivalence assessment in equivalence studies with intercurrent events and can be applied to comparative biosimilar clinical trials and non-inferiority trials. Recent Publications Lou Y, Jones M P and Sun W (2018) Estimation of causal effects in clinical endpoint bioequivalence studies in the presence of intercurrent events: noncompliance and missing data. Journal of biopharmaceutical statistics 1-23. LaVange L M and Permutt T (2016) A regulatory perspective on missing data in the aftermath of the NRC report. Statistics in Medicine 35(17):2853-2864. Permutt T (2016) A taxonomy of estimands for regulatory clinical trials with discontinuations. Statistics in Medicine 35(17):2865-2875. Permutt T (2016) Sensitivity analysis for missing data in regulatory submissions. Statistics in Medicine 35(17):2876-2879. Sun W, Zhou L, Grosser S and Kim C (2016) A meta-analysis of missing data and non-compliance data in clinical endpoint bioequivalence studies. Statistics in Biopharmaceutical Research 8(3):334-344.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Wanjie Sun”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels